At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 32 enrolled
Drug / intervention
BIA 2-093 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I, Open-label Drug Interaction Study Between Eslicarbazepine Acetate 1200mg and Phenytoin 300 mg Following Multiple Dose Administrations in Healthy Male Volunteers
In Brief
A Phase 1 clinical trial evaluating BIA 2-093 and Phenytoin for Epilepsy. Completed, enrolled 32 participants.
Detailed Summary
Single centre, open-label, multiple doses, two parallel study groups each receiving two formulations in a one-sequence design
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy
Countries--
Collaborators--
Timeline
Phase 1CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2007
Primary CompletionMar 2007
First PostedNov 2014
TodayJul 2026
First PostedNov 5, 2014
Enrollment StartJan 1, 2007
Primary CompletionMar 1, 2007
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 11.7 years ago
Interventions
BIA 2-093drug
Phenytoindrug